Xuehong Liu, Jingyao Ye, Wenlong Guo, Junqing Wang
{"title":"外泌体在骨肉瘤研究中的意义:一项单一临床研究的系统回顾和荟萃分析。","authors":"Xuehong Liu, Jingyao Ye, Wenlong Guo, Junqing Wang","doi":"10.3389/fcell.2024.1473044","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Osteosarcoma is the most prevalent among primary bone malignancies, and its standard intervention involves neoadjuvant chemotherapy - surgical adjuvant chemotherapy (MAP regimen) with adriamycin, cisplatin, and high-dose methotrexate. Early-stage osteosarcoma can be effectively treated with surgical resection along with chemotherapy or radiotherapy. However, as the cancer progresses, the efficacy of chemo- and radiotherapy decreases, and the associated problems increase. The current understanding of osteosarcoma development, diagnosis, and treatment does not meet clinical demands. More recently, there has been a significant increase in exosome-associated osteosarcoma research, potentially opening up novel possibilities for osteosarcoma research.</p><p><strong>Purpose: </strong>We comprehensively evaluated and analyzed the advancement of preclinical research related to exosome-osteosarcoma. We aimed to establish a practical, theoretical foundation for future research initiatives.</p><p><strong>Study design: </strong>The selected design was a systematic review and meta-analysis.</p><p><strong>Methods: </strong>Scientific databases, such as PubMed, Embase, The Cochrane Library, and Web of Science, were extensively screened for exosome and osteosarcoma articles. Two highly trained investigators separately reviewed the literature, extracted relevant information, and assessed study quality. Subsequently, we conducted a meta-analysis using Review Manager 5.4.</p><p><strong>Results: </strong>In total, 25 animal-based randomized controlled trials (RCTs) were selected for analysis. Among them, 13 studies provided strong evidence of cellular exosomes regulating osteosarcoma development from bone marrow mesenchymal stem cells, osteosarcoma cells, and macrophages. In addition, 12 studies demonstrated the therapeutic potential of exosomes in managing osteosarcoma, among which 7 studies transplanted transfected exosomes directly into animals as drugs, and five studies employed exosomes as drug carriers, which were next transplanted into animals.</p><p><strong>Conclusion: </strong>Based on our meta-analysis, macrophages strongly modulate osteosarcoma development, and engineered exosomes provide the most effective exosome-based osteosarcoma treatment.</p>","PeriodicalId":12448,"journal":{"name":"Frontiers in Cell and Developmental Biology","volume":"12 ","pages":"1473044"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599209/pdf/","citationCount":"0","resultStr":"{\"title\":\"Significance of exosomes in osteosarcoma research: a systematic review and meta-analysis of a singular clinical investigation.\",\"authors\":\"Xuehong Liu, Jingyao Ye, Wenlong Guo, Junqing Wang\",\"doi\":\"10.3389/fcell.2024.1473044\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Osteosarcoma is the most prevalent among primary bone malignancies, and its standard intervention involves neoadjuvant chemotherapy - surgical adjuvant chemotherapy (MAP regimen) with adriamycin, cisplatin, and high-dose methotrexate. Early-stage osteosarcoma can be effectively treated with surgical resection along with chemotherapy or radiotherapy. However, as the cancer progresses, the efficacy of chemo- and radiotherapy decreases, and the associated problems increase. The current understanding of osteosarcoma development, diagnosis, and treatment does not meet clinical demands. More recently, there has been a significant increase in exosome-associated osteosarcoma research, potentially opening up novel possibilities for osteosarcoma research.</p><p><strong>Purpose: </strong>We comprehensively evaluated and analyzed the advancement of preclinical research related to exosome-osteosarcoma. We aimed to establish a practical, theoretical foundation for future research initiatives.</p><p><strong>Study design: </strong>The selected design was a systematic review and meta-analysis.</p><p><strong>Methods: </strong>Scientific databases, such as PubMed, Embase, The Cochrane Library, and Web of Science, were extensively screened for exosome and osteosarcoma articles. Two highly trained investigators separately reviewed the literature, extracted relevant information, and assessed study quality. Subsequently, we conducted a meta-analysis using Review Manager 5.4.</p><p><strong>Results: </strong>In total, 25 animal-based randomized controlled trials (RCTs) were selected for analysis. Among them, 13 studies provided strong evidence of cellular exosomes regulating osteosarcoma development from bone marrow mesenchymal stem cells, osteosarcoma cells, and macrophages. In addition, 12 studies demonstrated the therapeutic potential of exosomes in managing osteosarcoma, among which 7 studies transplanted transfected exosomes directly into animals as drugs, and five studies employed exosomes as drug carriers, which were next transplanted into animals.</p><p><strong>Conclusion: </strong>Based on our meta-analysis, macrophages strongly modulate osteosarcoma development, and engineered exosomes provide the most effective exosome-based osteosarcoma treatment.</p>\",\"PeriodicalId\":12448,\"journal\":{\"name\":\"Frontiers in Cell and Developmental Biology\",\"volume\":\"12 \",\"pages\":\"1473044\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599209/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cell and Developmental Biology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.3389/fcell.2024.1473044\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cell and Developmental Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fcell.2024.1473044","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:骨肉瘤是最常见的原发性骨恶性肿瘤,其标准干预措施包括新辅助化疗--阿霉素、顺铂和大剂量甲氨蝶呤的手术辅助化疗(MAP方案)。早期骨肉瘤可通过手术切除、化疗或放疗得到有效治疗。然而,随着癌症的进展,化疗和放疗的疗效会下降,相关问题也会增加。目前人们对骨肉瘤的发展、诊断和治疗的认识还不能满足临床需求。最近,与外泌体相关的骨肉瘤研究显著增加,可能为骨肉瘤研究带来新的可能性。目的:我们全面评估和分析了与外泌体-骨肉瘤相关的临床前研究进展。研究设计:研究设计:所选设计为系统综述和荟萃分析:我们在 PubMed、Embase、The Cochrane Library 和 Web of Science 等科学数据库中广泛筛选了有关外泌体和骨肉瘤的文章。两名训练有素的研究人员分别审阅文献,提取相关信息并评估研究质量。随后,我们使用Review Manager 5.4.Results进行了荟萃分析:我们共选择了 25 项动物随机对照试验 (RCT) 进行分析。其中,13项研究提供了强有力的证据,证明来自骨髓间充质干细胞、骨肉瘤细胞和巨噬细胞的细胞外泌体可调节骨肉瘤的发展。此外,12 项研究证明了外泌体在治疗骨肉瘤方面的潜力,其中 7 项研究将转染的外泌体作为药物直接移植到动物体内,5 项研究将外泌体作为药物载体,然后再移植到动物体内:根据我们的荟萃分析,巨噬细胞对骨肉瘤的发展有强烈的调节作用,而工程外泌体能提供最有效的基于外泌体的骨肉瘤治疗。
Significance of exosomes in osteosarcoma research: a systematic review and meta-analysis of a singular clinical investigation.
Background: Osteosarcoma is the most prevalent among primary bone malignancies, and its standard intervention involves neoadjuvant chemotherapy - surgical adjuvant chemotherapy (MAP regimen) with adriamycin, cisplatin, and high-dose methotrexate. Early-stage osteosarcoma can be effectively treated with surgical resection along with chemotherapy or radiotherapy. However, as the cancer progresses, the efficacy of chemo- and radiotherapy decreases, and the associated problems increase. The current understanding of osteosarcoma development, diagnosis, and treatment does not meet clinical demands. More recently, there has been a significant increase in exosome-associated osteosarcoma research, potentially opening up novel possibilities for osteosarcoma research.
Purpose: We comprehensively evaluated and analyzed the advancement of preclinical research related to exosome-osteosarcoma. We aimed to establish a practical, theoretical foundation for future research initiatives.
Study design: The selected design was a systematic review and meta-analysis.
Methods: Scientific databases, such as PubMed, Embase, The Cochrane Library, and Web of Science, were extensively screened for exosome and osteosarcoma articles. Two highly trained investigators separately reviewed the literature, extracted relevant information, and assessed study quality. Subsequently, we conducted a meta-analysis using Review Manager 5.4.
Results: In total, 25 animal-based randomized controlled trials (RCTs) were selected for analysis. Among them, 13 studies provided strong evidence of cellular exosomes regulating osteosarcoma development from bone marrow mesenchymal stem cells, osteosarcoma cells, and macrophages. In addition, 12 studies demonstrated the therapeutic potential of exosomes in managing osteosarcoma, among which 7 studies transplanted transfected exosomes directly into animals as drugs, and five studies employed exosomes as drug carriers, which were next transplanted into animals.
Conclusion: Based on our meta-analysis, macrophages strongly modulate osteosarcoma development, and engineered exosomes provide the most effective exosome-based osteosarcoma treatment.
期刊介绍:
Frontiers in Cell and Developmental Biology is a broad-scope, interdisciplinary open-access journal, focusing on the fundamental processes of life, led by Prof Amanda Fisher and supported by a geographically diverse, high-quality editorial board.
The journal welcomes submissions on a wide spectrum of cell and developmental biology, covering intracellular and extracellular dynamics, with sections focusing on signaling, adhesion, migration, cell death and survival and membrane trafficking. Additionally, the journal offers sections dedicated to the cutting edge of fundamental and translational research in molecular medicine and stem cell biology.
With a collaborative, rigorous and transparent peer-review, the journal produces the highest scientific quality in both fundamental and applied research, and advanced article level metrics measure the real-time impact and influence of each publication.